Helaina Raises $45M to Commercialize First Precision-Fermented Human Lactoferrin
US precision fermentation company Helaina has raised $45 million in Series B funding to scale and commercialize its first product, effera Human Lactoferrin. Effera, claimed to be the first and only human lactoferrin available, is a bioactive ingredient that supports women’s health, active nutrition, and healthy aging. According to the startup, clinical and pre-clinical research indicates it is even more effective than bovine lactoferrin. The round, led by Avidity Partners, brought Helaina’s total equity funding to $83 million. Spark Capital, Ingeborg Investments, Tom Williams of Heron Rock, Barrel Ventures, Siam Capital, Relish Works, CF Private Equity, and Primary Venture Partners, among others, also backed the first company to put human proteins into food. Founder and CEO Laura Katz shared, “This infusion of new capital marks …